Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Exelixis
- Study ID
- NCT06943755
- Phase
- PHASE2/PHASE3
- Status
- Recruiting
Conditions
- Extra-Pancreatic Neuroendocrine Tumor (epNET)
- Pancreatic Neuroendocrine Tumor (pNET)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Zanzalintinib — DRUGAdministered as specified in the treatment arm.
- Everolimus — DRUGAdministered as specified in the treatment arm.
Study Details
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Key Dates
- First listed
- Apr 24, 2025
- Start date
- Jul 21, 2025
- Status verified
- Jul 2026
- Primary completion
- Jun 30, 2029
- Completion
- Jun 30, 2029
Study Design
- Enrollment
- 440 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: EverolimusParticipants will receive everolimus oral tablets once daily.
- Experimental: ZanzalintinibParticipants will receive zanzalintinib oral tablets once daily.
Primary Outcome Measure
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) [ Time Frame: Up to 48 months ]
Central Contacts
- Exelixis Clinical Trials1-888-EXELIXIS (888-393-5494)
- Backup or International650-837-7400